• Clinical features of uterine fibroids in the postmenopausal period
To content

Clinical features of uterine fibroids in the postmenopausal period

HEALTH OF WOMAN. 2019.5(141): 69–72; doi 10.15574/HW.2019.141.69

Garashova M. A., Aliyeva E. M.
Azerbaijan Medical University, Baku

The objective: to study the clinical manifestations of uterine fibroids in the postmenopausal period.

Materials and methods. 85 patients with uterine myoma in the postmenopausal period were examined. The average age of patients was 58±1.0 (47–80) years. Criteria of inclusion are all patients with uterine myoma of up to 12 weeks of gestation of various localization in the postmenopausal period .In all patients, the clinical and anamnestic manifestations of uterine fibroids were studied. The state of the hypothalamic-pituitary-ovarian system, the determination of the level of the CA 125 tumor.

Results. In 47 (55.3%) patients, various clinical manifestations of uterine fibroids were noted: in 37 (78.7%) patients there was pain of varying intensity, in 22 (46.8%) of patients was bloody discharge, in 17 (36.2%) dysuric phenomena, 10 (21.3%) patients had bleeding and 10 (21.3%) patients had defecation disorders.

In 34 (72.3%) patients, the presence of menopausal syndrome of varying severity was noted. At the same time, the frequency of mild menopausal syndrome was 23.4% (n=11), moderate climacteric syndrome was 21.3% (n=10), and the frequency of severe degree was 27.7% (n=13).

In patients with uterine myoma in the postmenopausal period, there was a significant increase in Prl, DHEA-S, E1 and a significant decrease in the LH / FSH ratio, E2, and Ttot (P<0.05). The changes in the level of the CA125 tumor marker were insignificant and did not represent diagnostic value.

Conclusion. Data analysis of the results of this study demonstrated that the main factors affecting the growth and development of uterine fibroids in postmenopause are the presence of hyperprolactinemia, hyperandrogenism of adrenal genesis and hyperestrogenia due to an increase in estrone level, which leads to an imbalance of apoptosis and proliferation mechanisms.

Key words: uterine myoma, postmenopausal period, bleeding, hyperandrogenism, hypoestrogenism, climacteric syndrome.

REFERENCES

Kondratovich LM. 2014. Sovremennyiy vzglyad na etiologiyu, patogenez i sposobyi lecheniya miomyi matki. Rossiyskiy meditsinskiy zhurnal 5: 36–40.

Lebedev VA, Davyidov AI, Pashkov VM. 2013. Spornyie i ne reshennyie voprosyi lecheniya i profilaktiki miomy matki u bolnyih reproduktivnogo perioda. Zh. Trudnyiy patsient 8–9:14–19.

Samoylova TE. 2010. Neoperativnyie metodyi lecheniya miomy matki. Zh. Lechaschiy vrach 3: 53–60.

Tihomirov AL. 2013. Mioma, patogeneticheskoe obosnovanie organosohranyayuschego lecheniya. M: 319.

Baird DD, Hill MC, Schectman JM, Hollis BW. 2013. Vitamin D and the risk of uterine fibroids. Epidemiology 24:447–453. https://doi.org/10.1097/EDE.0b013e31828acca0; PMid:23493030 PMCid:PMC5330388

Coddington CC, Grow DR, Ahmed MS, Toner JP. 2009. Gonadotropin-releasing hormone agonist pretreatment did not decrease postoperative adhesion formation after abdominal myomectomy in a randomized control trial. Fertil.Steril. 91;5:1909–1913. https://doi.org/10.1016/j.fertnstert.2008.02.128; PMid:18439584

Duhan N, Madaan S, Sen J. 2013. Role of the aromatase inhibitor letrozole in the management of uterine leiomyomas in premenopausal women. Eur.J.Obstet.Gynecol.Reprod Biol.  171;2: 329–332. https://doi.org/10.1016/j.ejogrb.2013.09.010; PMid:24103533

Henri Mater, Xavier F, Lobna Ouldamer. 2012. Therapeutic management of terine fibroib tumors: update French guidelines. Eur.J. Obstet.Gynecol.Reprod Biol. 165:156–164. https://doi.org/10.1016/j.ejogrb.2012.07.030; PMid:22939241

Laughlin SK, Schroeder JC, Baird DD. 2010. New directions in the epidemiology of uterine fibroids. Seminars in Reproductive Medicine 28;3:204–217. https://doi.org/10.1055/s-0030-1251477; PMid:20414843 PMCid:PMC5330647

Litta P, Conte L, De Marchi F, Saccardi C, Angioni S. 2013. Pregnancy outcome after hysteroscopic myomectomy. Gynecol.Endocrinol. 5. https://doi.org/10.3109/09513590.2013.863861; PMid:24303914

Ludwin A, Ludwin I, Pityński K, Basta P, Basta A. 2013. Transrectal ultrasound-guided hysteroscopic myomectomy of submucosal myomas with a varying degree of myometrial penetration. J.Minim.Invasive Gynecol. 20;5: 672–685. https://doi.org/10.1016/j.jmig.2013.05.001; PMid:23850363

Sato K, Yuasa N, Fujita M, Fukushima Y. 2013. Clinical application of diffusion-weighted imaging for preoperative differentiation between uterine leiomyoma and leiomyosarcoma. Am.J. Obstet.Gynecol. 21.

Spies JB. 2013. Current evidence on uterine embolization for fibroids. Semin.Intervent.Radiol. 30;4:340–346. https://doi.org/10.1055/s-0033-1359727; PMid:24436560 PMCid:PMC3835459

Zhang Y, Hua KQ. 2014. Patient’s age, myoma size, muoma location, and interval between myomectomy and pregnancy may influence the pregnancy rate and live birth rate after myomectomy. J. Laparoendosc.Adv. Surg. Tech. A. 24;2:95–99. https://doi.org/10.1089/lap.2013.0490; PMid:24368007 PMCid:PMC3935437